Market Overview

Why Citius Pharmaceuticals Is Trading Higher Today


Citius Pharmaceuticals (NASDAQ: CTXR) is trading higher after signing an exclusive option with Novellus to license its Novel Stem-Ce; Therapy for acute respiratory distress syndrome associated with Coronavirus.

Citius is a pharmaceutical company, developing and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections.

Citius Pharmaceuticals shares were trading up 29.98% to 78 cents in Wednesday’s pre-market session. The stock has a 52-week high of $1.50 and a 52-week low of 40 cents.


Related Articles (CTXR)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks Markets Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at